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Capsule: High levels of EG-VEGF expression may play an important role in 
angiogenesis in endometriotic tissues.
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Abstract
Objective: To study the expression of vascular endothelial growth factor (VEGF), 
endocrine gland-derived VEGF (EG-VEGF/PK1) and its receptors (PKR1 and PKR2) 
in eutopic and ectopic endometrial tissues. Design: A case control study. Setting: 
University reproduction unit. Patients: Infertile women undergoing diagnostic 
laparoscopy for tubal patency. Intervention: Endometrial and endometriotic tissue 
sampling from women with and without endometriosis. Main Outcome Measure(s): 
Quantitative PCR analysis of genes in eutopic and ectopic endometrial tissues.
EG-VEGF protein was studied by immunohistochemistry. Result(s): In normal 
endometrium, EG-VEGF mRNA expression was 50-fold higher (p<0.05) in the 
secretory than in the proliferative phase, but that of PKR1 was 6-fold higher in the 
latter than in the former. PKR2 transcript was detected in the proliferative but not the 
secretory endometrium. In patients with endometriosis, eutopic endometrial PKR2
transcript level was 4-fold higher (p<0.05) in the proliferative than in the secretory 
phase. No differences in EG-VEGF nor PKR1 in proliferative versus secretory 
endometrium in these patients were found. There were no significant differences in 
the expression of EG-VEGF in eutopic endometrium of normal women and those with 
endometriosis. In the paired laser captured micro-dissected eutopic endometrial and 
ectopic endometriotic samples, a significantly higher (p<0.01) EG-VEGF but not 
VEGF transcript level was detected in the ectopic when compared to eutopic samples;
while the expressions of PKR1 and PKR2 were barely detectable. H-scoring 
confirmed that the stroma of endometriotic samples had a significantly higher (p<0.05)
EG-VEGF protein expression than that in the paired eutopic endometrium.
Conclusion(s): High levels of EG-VEGF expression may play an important role in
angiogenesis in endometriotic tissues.
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INTRODUCTION
Endometriosis refers to the presence of endometrial tissues outside the uterine 
cavity. It occurs spontaneously in humans and non-human primates including baboons 
and macaques but is rare in other animal species (1). Endometriosis is a common 
gynaecological disease affecting 6-10% women of reproductive age. Affected women 
have higher risk than the general female population in developing cancers,
autoimmune and atopic disorders (2). Its etiology and pathophysiology are still 
unclear. Endometrial tissues in the uterus (eutopic) and outside the uterine cavity 
(ectopic) respond to the cyclical changes of steroid hormones. However, the 
proportions of estrogen and progesterone receptors, as well as the histology are 
different between paired eutopic and ectopic endometrial samples (3-5).
Angiogenesis is important in the development of endometriosis (6-8). 
Angiostatic treatment reduces the number of endometriotic lesions at implantation in 
the chick chorioallantoic membrane model (9) and after implantation in the nude mice 
model (10). Various growth factors including vascular endothelial growth factor 
(VEGF) have been found to be associated with angiogenesis in endometriosis (6, 10, 
11).
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF)
belongs to the prokineticin family. It is also known as prokineticin 1 (PK1), and
shares about 44% amino acid homology with prokineticin 2 (PK2) or Bv8 (12). 
EG-VEGF was previously thought to be selectively expressed in steroidogenic glands 
and stimulate the growth of endocrine gland endothelium (13). It promotes
proliferation, survival, and chemotaxis of endothelial cells from steriodogenic tissue, 
such as adrenal cortex capillary endothelial cells (14), but not those from other tissues, 
such as human umbilical vein endothelial cells and other non-endothelial cell types 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
F & S 5688 revision
7
(12, 13). Although EG-VEGF is structurally distinct from VEGF, they induce similar
angiogenic response in the ovary (15, 16).
EG-VEGF acts via G-protein coupled receptors, PKR1 and PKR2 (17, 18), 
and induces mitogen-activated protein kinase (MAPK) and Akt serine/threonine 
kinase phosphorylation in bovine adrenal capillary endothelial cells (17), HEK293 
(18), adrenal cortex-derived endothelial (ACE) cells (19), neuroblastoma cell line 
(SK-N-SH, 20) and human uterine microvascular endothelial cell (Ut-HVEC-Myo, 
21). Human PKR1 and PKR2 shared 85% amino acid identity and are most divergent 
in their N-terminal sequences (18).
Prokineticins and their receptors are likely to be involved in reproduction as 
they are expressed in male reproductive tissues including testis and prostate (22, 23), 
and in female reproductive tissues such as ovary, uterus and various tissues during 
pregnancy (16, 24, 25). EG-VEGF has also been implicated in the pathology of the 
reproductive tract (26), including Leydig cell neoplasms (27), prostate cancer (23), 
ovarian carcinoma (15) and polycystic ovarian syndrome (16). Whether EG-VEGF is 
involved in endometriosis is unclear. During early pregnancy and in hypoxic 
conditions, hypoxia-inducible factor-1 (HIF-1α) binds to the promoter of EG-VEGF 
and PKR1 leading to up-regulation of these genes in the placenta (13, 25, 26).
Interestingly, transient hypoxia also up-regulates HIF-1α and induces the 
expression of VEGF in endometrium (28) and transplanted endometriosis-like lesions 
(29). In the mice model, suppression of HIF-1α decreases VEGF production and 
inhibits growth of the transplanted endometriosis-like lesions (29).
Recently, EG-VEGF was found to be expressed in non-endocrine tissues 
including endometrium (26, 30, 31). In human endometrium, EG-VEGF is highly 
expressed in the secretory phase of the menstrual cycle when active angiogenesis 
occurs (30, 31). The facts that EG-VEGF is detected only in steroid (estradiol and 
progesterone) treated endometrial epithelial and stromal cells, and is up-regulated in 
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the peri-implantation endometrium after gonadotropin-stimulation and hormone 
replacement therapy suggests that the production of EG-VEGF is hormone dependent 
(30, 31). Despite all these observations, the function of EG-VEGF in the uterus 
remains unknown.
In view of the importance of angiogenesis in the development and progression 
of endometriosis, the involvement of multiple factors in the regulation of angiogenesis 
and HIF-1α target genes in endometriosis, and the potential angiogenic role of 
EG-VEGF in endometrium, we hypothesized that aberrant expression of EG-VEGF
could be associated with the pathogenesis of endometriosis. In this study, we used 
laser micro-dissection technique to isolate paired human eutopic and ectopic 
endometriotic biopsies for real-time PCR analysis on VEGF, EG-VEGF and PKR1 
and PKR2 mRNA expression. The increased expression of EG-VEGF mRNA and 
protein in ectopic endometriotic tissues suggests this molecule is associated with the 
progression of the disease.
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MATERIALS AND METHODS
Human Subjects
Infertile women with endometriosis shown on diagnostic laparoscopy for 
assessment of tubal patency were recruited. The eutopic endometrial (DE) samples 
from these diseased women (n=15) were obtained by pipelle. The American Society 
for Reproductive Medicine (ASRM) rAFS scoring was used to classify the stages of 
the disease. Eutopic endometrial samples were also taken from 33 normal women (NE) 
who had no endometriosis as determined by laparoscopic examination and had regular 
menstrual cycles. There were no difference between the mean age (normal: 33, range 
24-39; endometriosis: 34, range 29-38, p>0.05) and mean cycle length (normal: 30, 
range 26-35 days; endometriosis: 30, range 25-35 days, p>0.05) of the normal and the 
diseased groups. For the paired eutopic and ectopic endometriotic samples (n=16), 
tissues at proliferative phase (n=4) and secretory phase (n=12) were obtained from 
women with endometriosis (age: 31-49). All recruited subjects had not received any 
anti-inflammatory or hormonal medication for at least three months prior to the 
sample collection. The classification of the endometrial samples into proliferative or 
secretory phases was based on the day of the last menstrual period and was confirmed 
by endometrial histology (32). The Institutional Review Board of the University of 
Hong Kong/Hospital Authority Hong Kong West Cluster had approved the protocol 
of the study and informed consent was received from each subject.
Laser Captured Micro-dissection (LCM) and Real-time PCR
The endometrial and endometriotic tissues were snap-frozen, embedded in 
OCT medium and cut into 6 m thick sections at -20oC.  Ectopic endometrial 
samples containing glandular and stromal cells were isolated by laser captured 
micro-dissection (LCM) to avoid contamination by ovarian stromal tissue. Eutopic 
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endometrial samples were processed similarly as sham procedure before RNA 
extraction. In brief, frozen tissue sections were mounted on a membrane slide with a 2 
m thick membrane framed by aluminum and stained with hematoxylin and eosin for
histological examination. After drying in air for 10 min, the membrane slide was
placed on a regular glass slide, which was put on the microscopic stage with the 
membrane slide facing up (Leica DM IRB, Leica Microsystems Ltd.). Glandular and 
stomal tissues were micro-dissected using a laser beam (VSL-337ND-S nitrogen laser, 
Laser Science Inc.) and picked up by the capturing caps. The attached tissues were 
then put directly into microcentrifuge tubes. RNA from three captured tissues were 
extracted with the Absolute RNA Miniprep Kit (Stratagene, CA, USA) as described 
previously (33) and eluted with 30 l of distilled water. One-third of the total RNAs 
from each sample were reverse-transcribed into cDNA using the First-strand cDNA 
Synthesis Kit (Amersham Pharmacia, Buckinghamshire, UK). Real-time PCR 
analysis of human VEGF, EG-VEGF, PKR1 and PKR2 transcripts were performed 
using an ABI 7500 Sequence Detector (PE Applied Biosystems, Foster City, CA). 
Multiplex PCR reactions were carried out in a 20 μl reaction mixture containing 2 μl 
of sample cDNA; 10 μl 2X TaqMan Universal PCR Master Mix; 1 μl of 18S internal 
control and 1 μl of 20X Assays-on-Demand Gene Expression Assays (PE Applied 
Biosystems) in triplicates. The qPCR experiment was repeated thrice for the 16 pairs 
of RNA samples. Quantitative analysis was done by the sequence detection software 
supplied with the ABI 7500 Sequence Detector. The threshold cycles (Ct) for each 
reaction were calculated and used for quantifying the amount of starting template in 
the reaction. A difference of Ct values (Ct) was obtained by subtracting the Ct value 
of 18S from Ct value of the genes of interest. The relative gene expression values
were calculated by the 2-Ct method (34). The relative amount of the transcript of 
interest in the normal sample (X) and the diseased sample (Y) after normalization to 
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an endogenous reference (18S) was calculated as 2-Ctwhere Ct is the difference 
in Ct between the gene of interest and 18S, and Ct is the difference for sample X
and Y i.e. CtX - CtY.  The expression levels in normal endometrium or in 
proliferative phases were used as calibrators for different PCR experiments.
Immunohistochemical Staining
Antibody against human EG-VEGF was obtained from R&D Systems 
(MAB1209, Minneapolis, MN).  Frozen endometrial and testicular sections were 
acetone and then methanol fixed for 5 min and the tissues were blocked by 10% rabbit 
serum in PBS for 30 minutes. A 1:100 dilution of the antibody was used and the 
tissues sections were incubated at 4oC overnight.  The tissues were washed 5 times 
with PBS, incubated with 1:300 diluted rabbit anti-mouse biotinylated secondary 
antibody for 60 minutes, and were incubated with the ABC complex (Vectastain ABC 
kit, Vector, Burlingame, CA) for 30 min.  Specific signal were visualized by DAB 
staining and the tissues were counterstained with hematoxylin. Semi-quantitative
assessment of staining (n=12) was done on 5 fields of epithelial and stromal tissues by 
H-score (35), which was calculated as: H score = Pi(i+1), where i = staining 
intensity graded as 0, 1, 2 and 3 with 3 being the highest intensity, and Pi = 
percentage of tissue staining at each intensity.
Statistical Analysis
Data were analyzed using the SigmaPlot software package (Jandel Scientific, 
San Rafael, CA). Statistical analysis was performed by Kruskal–Wallis and 
Mann–Whitney U test or paired t-test as appropriate. Linear associations of American 
Society for Reproductive Medicine’s classification rAFS scores on the endometriosis 
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patients with EG-VEGF, PKR1 and PKR2 mRNA expression were tested using 
Pearson’s correlation coefficient. A p-value <0.05 was considered statistically 
significant.
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RESULTS
Expression of EG-VEGF, PKR1 and PKR2 in Normal and Eutopic 
Endometrial Tissues
To determine if there were differences in the mRNA expression levels of 
EG-VEGF, PKR1 and PKR2 between eutopic endometrium from normal women (NE,
n=33) and eutopic endometrium of diseased women with endometriosis (DE, n=15), 
tissue samples were divided into 4 groups: normal proliferative endometrium (n = 14),
normal secretory endometrium (n = 19); eutopic proliferative endometrium with 
endometriosis (n = 9) and eutopic secretory endometrium with endometriosis (n = 6). 
The relative expression of the three transcripts was normalized to 18S and calculated 
by the equation: 2-Ct using the proliferative phase normal endometrium (NE) as 
calibrator. It was found that normal endometrium (NE) at secretory phase expressed
significantly (p<0.05) higher EG-VEGF (50-fold) but lower PKR1 (6-fold) mRNA 
when compared with that of the normal proliferative phase samples (Table 1, Figure 
1A and B). PKR2 transcript was detected in the normal proliferative endometrium but 
not in the normal secretory endometrium. (Table 1 and Figure 1C). The expression of 
PKR2 in the eutopic proliferative endometrium from patients with endometriosis (DE; 
Table 1 and Figure 1C) was significantly higher (4-fold, p<0.05) than that in the 
eutopic secretory endometrium. However, no difference was found in EG-VEGF and 
PKR1 expression between the proliferative and secretory eutopic endometria from 
patients with endometriosis (Figure 1A and B). When the expression of the three 
genes in endometrial biopsies of the same menstrual phase was compared, no 
difference was found between the normal and the endometriosis groups. The rAFS
scores of the endometriosis patients ranges from 1 to 85 with a median value of 4. 
Analysis of the relationship between rAFS scores of the endometriosis patients and 
the mRNA expression of EG-VEGF, PKR1 and PKR2 had a coefficient of correlation 
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(r) of -0.136, 0.0122 and -0.0152, respectively (p>0.05), indicating that the gene 
expressions were not correlated with the rAFS scores (data not shown).
Expression of EG-VEGF, PKR1 and PKR2 in the Paired Eutopic and 
Ectopic Endometriotic Samples
We further analyzed the expression of VEGF and EG-VEGF mRNA in 
another sixteen paired human endometriotic samples (Figure 2A) in which 4 were in 
proliferative and 12 were in secretory phases by real-time PCR. The LCM isolated 
tissues from eutopic and ectopic samples contained a mixture of glandular and stromal 
tissues.  Multiplex real-time PCR were carried out and the data were normalized 
with 18S and calculated by the equation: 2-Ct using the ectopic endometrium as
calibrator.. No significant difference was found in VEGF expression (Figure 2B) 
between the eutopic and ectopic endometiotic samples (1.922 vs 1.151, p>0.05), but a 
significant increase in EG-VEGF expression (Figure 2B) between the eutopic and 
ectopic endometriotic samples (0.140 vs 2.131, p=0.00879) was observed.  Subgroup 
analysis of the secretory phase samples demonstrated the expression of EG-VEGF in 
ectopic endometrium is significantly higher than that of the eutopic endometrium 
(0.202 vs 1.970, p=0.0159); while no significant change in VEGF expression was 
found. Very low or undetectable expression of PKR1 and PKR2 were observed, i.e. Ct 
value close to 40 cycles, in both the eutopic and ectopic endometriotic samples (data 
not shown).
EG-VEGF Protein Expression in Ectopic Endometriotic Tissues
Immunohistochemical staining was performed using EG-VEGF antibody on 
frozen paired endometrial tissues. EG-VEGF immunoreactivity was strongly localized 
to the glandular and luminal epithelium of the eutopic endometrial samples (Figure 
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3A) and the expression of EG-VEGF in the stromal cells were weak.  In ectopic 
endometriotic samples, intense EG-VEGF immunostaining was found in the stromal 
cells (Figure 3B). No immunostaining was found when the primary antibody was 
omitted (Figure 3C). The specificity of the antibody was confirmed when frozen 
human testicular section was used (Figure 3D) and specific signal was observed in the 
Leydig cells of the testis. The expression of EG-VEGF protein in twelve pairs of 
endometriotic samples was determined by H-scoring (Figure 3E and F).  Significant 
difference was found in the stromal cells (Median and range: 1.5 (0.5-2.4) vs 0.5 
(0-2.2), p=0.011), but not in the glandular epithelium (Median and range: 1.4 (0.2-2.0) 
vs 1.5 (1.0-2.4), p>0.05) of ectopic and eutopic sample, respectively.
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DISCUSSION
The expression of EG-VEGF in human endometrium was up-regulated in the 
secretory phase of the menstrual cycle (Figure 1A), consistent with a steroid 
regulatory mechanism of EG-VEGF production. Higher expression of EG-VEGF was 
also found in the gonadotropin-stimulated cycle when compared with the natural cycle 
of patients undergoing assisted reproduction treatment (30). The hormonal regulation 
of EG-VEGF expression by progesterone has also been demonstrated using cultured 
endometrial tissues (31). Furthermore, our recent study demonstrated that estrogen 
and/or progesterone stimulate EG-VEGF expression in the human primary 
endometrial stromal and glandular epithelial cells (30).
We detected a higher PKR1 and PKR2 mRNA expression in eutopic 
endometrial samples from normal women (NE) in the proliferative phase (Figure 1B 
and C) than in the secretory phase suggesting that the receptors for EG-VEGF (PKR1 
and PKR2) may be mainly regulated by estrogen. The differential expression pattern 
of PKR2, but not PKR1, was also found in the proliferative and secretory eutopic 
endometria from patients with endometriosis (DE). However, no significant temporal 
variation of PKR1 and PKR2 mRNA expression was found between the human
proliferative and secretory endometria in another study (31). The reasons for this 
discrepancy remain unknown. It could be due to the inclusion of the full-thickness of 
the endometrium with basal endometrial-myometrial region expressing low level of 
PKR2 in the previous study, whereas only the superficial endometrial layer was 
analyzed in the present study.
It was interesting to note that the level of EG-VEGF was low whilst that of the 
transcripts of EG-VEGF receptors (PKR1 and PKR2) was up-regulated in the 
proliferative endometrium when compared to the secretory endometrium in normal 
samples. The reason for the dissonance in the expression between EG-VEGF and its 
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receptors was not clear. It was possible that EG-VEGF/PK1 could act on another 
receptor yet to be defined in the secretory endometrium. In line with this,
endometrium expresses another ligand of PKR1 and PKR2, PK2 with level that does 
not vary significantly in the menstrual cycle (31). PK2 has a long form spliced variant,
PK2L, which is co-expressed with PK2 in many tissues (36). PK2L produces a 
peptide, PK2 that can selectively activate PKR1 (36). The abundance of PK2L in 
endometrium at different phases of the menstrual cycle is not known. Its 
determination would be useful to verify the existence of the second possibility.
PKR1 and PKR2 share 87% homology in amino acid sequences and have 
almost identical transmembrane domain sequence (37), suggesting that they may have 
similar activation mechanism (26). However, it was reported that EG-VEGF induces
phosphorylation of p44/42 MAPK in the PKR1 transfected cells but not in the PKR2 
transfected cells (18). In mouse, PKR2 is essential for the maturation of the 
reproductive system as its deficiency is associated with atrophy of the reproductive 
tract including gonads and endometrium, which has been linked to the lack of 
gonadotropin-releasing hormone neurons in the hypothalamus (38). Yet, no 
abnormality in the reproductive tract of PKR1 knockout mice was found (38, 39).
When endometrial tissues in the same menstrual phase were compared, there 
was no significant difference in the mRNA expression of EG-VEGF and its receptors
between the normal endometrium and eutopic endometrium from women with 
endometriosis, indicating that eutopic EG-VEGF expression was not associated with 
the occurrence of endometriosis. This observation was supported by the present 
results showing no correlation between the severity of endometriosis (ASRM 
endometriosis scores) and the mRNA expression of EG-VEGF, PKR1 and PKR2 in 
the eutopic endometrium.
Human ovary abundantly expresses EG-VEGF and PKR2 but not PKR1 (14, 
18). In order to avoid contamination of endometriotic tissues by neighboring ovarian 
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tissue, we used laser captured micro-dissection to isolate endometriotic tissues. The 
purity of the laser micro-dissected samples was demonstrated by the very low or 
undetectable level of PKR2, which is known to be produced abundantly in the ovary. 
The micro-dissected ectopic endometriotic tissues used in this study contained both 
epithelial and stromal cells. They produced EG-VEGF but not its receptors, 
suggesting paracrine actions of the EG-VEGF most probably act on the neighboring 
ovarian cells which express PKR2. Consistent with this possibility is the observation 
that over-expression of EG-VEGF in the rat ovary resulted in excessive angiogenesis 
and cysts formation (13). Thus, the increase in EG-VEGF expression in ectopic 
endometrium when compared with that in the eutopic endometrium is likely to be an 
event secondary to the initiation of ovarian endometriosis. The expression of 
EG-VEGF is also associated with polycystic ovary syndrome (16). The aetiology of 
EG-VEGF over-expression in ovarian endometriotic cyst warrants further 
investigation.
Angiogenesis is important in the establishment and growth of endometriosis.
In the ovary, the angiogenic response induced by EG-VEGF is indistinguishable from 
that by VEGF (14).  However, the expression of ovarian EG-VEGF and VEGF is 
temporally and spatially complementary to each other (16), suggesting that the two 
growth factors have distinct roles and targets in ovarian functions. This may explain 
why up-regulated levels of EG-VEGF could induce pathophysiological changes in 
endometriosis even in the presence of other potent angiogenic factors like VEGF.
In the present study, a significant increase in EG-VEGF protein expression
was found in the stromal cells of ectopic endometrium (Fig. 3B and E). It is possible
that the stromal cells may synthesize more EG-VEGF and/or EG-VEGF is 
synthesized in the epithelial cells but is accumulated in the extracellular matrix of the 
stroma. The latter explanation was supported by the fact that VEGF binds to the 
extracellular matrix upon secretion (40) and releases during tissue breakdown or 
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hypoxia. EG-VEGF is a heparin-binding molecule (13) and the heparin-binding 
domain of VEGF interacts with the matrix proteins (41). Thus, EG-VEGF may also be 
accumulated in the extracellular matrix giving an intense immuno-positive signal. The 
current data cannot distinguish these two possibilities.
VEGF is generally accepted as a critical angiogenic factor associated with 
implantation and early pregnancy (42), though there are opposing opinions (43, 44).
Although the expression of VEGF mRNA and protein was higher in red peritoneal
endometriotic lesion than in other type of peritoneal lesions (45, 46), no difference in 
the mRNA expression of VEGF between eutopic endometrium and ovarian 
endometriotic tissues was found in the present study. This observation supports a 
recent report on lack of difference in VEGF immunorectivities between eutopic 
endometrium and ovarian endometriosis (47). There is also no difference in the 
mRNA and protein production of VEGF by granulose-luteal cells in women with or 
without ovarian endometriomas (48).
In conclusion, we have demonstrated an up-regulation of EG-VEGF but not 
VEGF in ectopic endometriotic tissues obtained from same patients. The absence
and/or low expression of EG-VEGF receptors (PKR1 and PKR2) in the ectopic 
endometriotic tissues suggested that EG-VEGF may act as paracrine and endocrine 
factors to promote angiogenesis in adjacent tissues leading the paracrine disorder in 
women. Further studies on the functional role of EG-VEGF, PKR1, PKR2 and VEGF 
on the pathophysiological changes in ectopic endometrium in vitro and in animal 
model will provide a better understanding on the causes of endometriosis and may 
lead to possible medical treatments for the prevention of this disease.
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Figure Legends
Figure 1
Real-time PCR analysis of EG-VEGF, PKR1 and PKR2 mRNA expression levels 
between normal and eutopic endometrium. Eutopic endometrial samples from 
normal women (NE) in proliferative (Proli, n = 14) and secretory phase (Sec, n = 19); 
and from women with endometriosis (DE) in proliferative (n = 9) and secretory phase
(n = 6) were studied. The relative expression of the (A) EG-VEGF, (B) PKR1 and (C) 
PKR2 mRNA expressions were normalized to 18S expression and calculated by the
equation: 2-Ct using the proliferative phase normal endometrium (NE) as calibrator. 
A difference of Ct values (Ct) was obtained by subtracting the Ct value of 18S from 
Ct value of the genes of interest. The relative gene expression values were calculated 
by the 2-Ct method (see materials and methods). Data were presented as median with 
10th, 25th, 75th and 90th percentiles and outliers (●). Statistical analysis was performed 
by Kruskal-Wallis test and p-values were shown. A p-value less than 0.05 was 
considered significant different from different samples.
Figure 2
Real-time PCR analysis of EG-VEGF and VEGF mRNA expression levels in 
paired LCM isolated eutopic and ectopic endometriotic samples. (A) Three LCM 
sections from ectopic or eutopic samples were used for RNA extraction. (B) The
relative expressions of EG-VEGF and VEGF transcripts were normalized to 18S and 
calculated by the equation: 2-Ct using the ectopic endometrium as calibrator. A 
p-value less than 0.05 was considered significant different from different samples. NS: 
Not significant.
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Figure 3
Immunohistochemical staining of EG-VEGF in eutopic and ectopic endometrium. 
Frozen eutopic (A and C) and ectopic (B) endometrial, and archive testis (D) samples 
were stained with EG-VEGF (A, B and D) antibody.  Specific brown signal was 
found in the glandular (GE) and luminal epithelium (LE) of eutopic endometrium (A), 
and in the stromal cells (SC) of the ectopic endometrium (B) of the same patient and 
no signal was found when the primary antibody was omitted (C). Leydig cells (Le) of 
frozen human testicular sample were positively stained with EG-VEGF antibody, but 
not in spermatozoa (Sp) in the seminiferous tubule (D). The expression of EG-VEGF 
protein in twelve pairs of endometriotic samples was determined by H-scoring.  
Significant difference was found in the stromal cells (E), but not glandular epithelium
(F) of ectopic and eutopic endometrium (p=0.011).
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Table 1 Messenger RNA expression of EG-VEGF, PKR1 and PKR2 in eutopic 
endometria of normal women and diseased women with endometriosis. The transcript 
expression levels were expressed as median of Ct values (ranges). * P<0.05 when 
compared with the proliferative phase.
mRNA
Normal women Women with endometriosis
Proliferative Secretory Proliferative Secretory
EG-VEGF
0.03 a
(5.210-6-1.0)
1.50 a
(0.0-27.9)
0.04
(2.910-4-0.6)
0.28 
(2.010-4-5.6)
PKR1
3.92 b
(0.0-23.4)
0.64 b
(0.0-6.7)
1.89 
(0.1-5.5)
0.43
(0.0-2.1)
PKR2
0.75 c
(0.0-6.6)
0.00 c
(0.0-1.0)
0.93 d
(0.0-10.7)
0.24 d
(0.0-1.2)
a-a, b-b, c-c, d-d are statistically difference (p<0.05) between groups
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